According to Visiongain forecasts, the infertility drugs and devices market will grow at a CAGR of 6.2% until 2034.

Visiongain has published a new report titled Report on the market of drugs and devices used in the treatment of infertility in the years 2024-2034: Forecasts by product (drugs, equipment, media and consumables, accessories), by procedure (assisted reproductive technologies, artificial insemination, infertility surgeries, other), by patient (female, male), by end use (fertility centers, hospitals and Surgical Clinics, Cryobanks, Research Institutes) AND Analysis of the regional and leading market in the country PLUS Analysis of leading companies.

The infertility drugs and devices market was valued at USD 5.9 billion in 2024 and is projected to grow at a CAGR of 6.2% during the forecast period 2024–2034.

Declining fertility rate

According to the UN Population Fund, fertility has fallen from 5 births in 1950 to 2.3 births per woman in 2021, and is expected to decline further to 2.1 births per woman by 2050 globally. About 75% of countries will not be able to sustain their population by 2050, which will increase to 97% of countries by 2100 due to falling fertility rates. The main causes of declining fertility rates are lifestyle factors such as nutrition, weight and physical activity; physical and mental stress; environmental and occupational exposure; substance and drug abuse; medications, tight work life balance, easy access to family planning methods/high contraceptive prevalence rate, late marriages etc. These factors are expected to increase the demand for infertility treatment, thereby contributing to the growth of the market.

Download an exclusive report sample
https://www.visiongain.com/report/infertility-treatment-market-2024/#download_sampe_div

How will this report benefit you?

The 351-page Visiongain report contains 160 tables, 249 charts and graphs. Our new study is suitable for anyone who needs commercial, in-depth analysis of the infertility drugs and devices market, along with detailed analysis of segments in the market. Our new study will help you evaluate the overall global and regional infertility drugs and devices market. Get financial analysis of the entire market and various segments, including market share for products, procedures, patients and end users. We believe there are significant opportunities in this rapidly growing market for infertility medications and devices. See how to leverage existing and upcoming opportunities in this market to gain revenue benefits in the near future. Additionally, the report will help you improve your strategic decision-making, enabling you to develop growth strategies, strengthen your analysis of other market participants, and maximize your company’s productivity.

The story continues

What are the current market drivers?

Increasing public-private investment

The increase in investments in the form of grants and funding is expected to boost the market growth. According to Crunchbase, a database company, the global investments have increased by 89% from $93 million in 2020 to $176 million in 2021. Moreover, as per UCLA Health, 15% of couples who are having trouble conceiving would expect help from employers or innovation from infertility treatment startups in the US. Moreover, acquisition of infertility treatment centers is another factor that is expected to trigger growth through organic and inorganic growth strategies. For example, in July 2023, BPEA EQT acquired 60% stake in Indira IVF Hospital Pvt. Ltd from TA Associates for $1.1 billion. Additionally, in May 2023, Morgan Health committed $25 million to a network of fertility clinics and employer benefits provider Kindbody, which offers the full spectrum of reproductive care from preconception to postpartum and menopause.

Increasing fertility tourism

The rising incidence of infertility and the resulting increase in medical costs in the US, coupled with advances in reproductive technologies abroad, have fueled interest in fertility tourism. The fertility tourism market is expected to grow by 30% between 2021 and 2028, reaching $400 million in 2021 globally. For example, fertility tourism is growing in Barbados due to the obvious differences in costs. Egg freezing at the Barbados Fertility Clinic costs $4,950, IVF costs $6,500, and genetic testing costs $2,000, compared to the $25,000 for a single round of IVF in the US. India is also a major destination for commercial surrogacy and is expected to be worth $445 million annually

Get detailed ToC
https://www.visiongain.com/report/rynek-leczenia-niepłodności-2024/

Where are the market opportunities?

Technological progress

The increasing technological advancement to enhance fertility is expected to drive the market growth. In May 2022, a research team led by the University of Adelaide with support from the Australian Research Council and The Hospital Research Foundation Group in collaboration with Fertilis unveiled a new micro-device to improve the only available infertility treatment for men with low sperm counts. The first-of-its-kind device will allow IVF clinics to offer intracytoplasmic sperm injection (ICSI) as a treatment and help improve procedures such as embryo culture, embryo cryopreservation, and in vitro maturation. The device entered global clinical trials in 2022.

Moreover, the latest developments in fertility health are focused on bringing clinical data and workflows to the digital age. Electronic systems that use barcodes to track sperm, eggs and embryos, robotic cryopreservation systems and artificial intelligence (AI)-based tools help improve reproductive health. Additionally, companies like Alife Health are focused on optimizing patients’ IVF process, ensuring optimal outcomes and lowering the overall cost of care.

Thanks to technological advances, it has become possible to perform an ultrasound examination at home, which the doctor will be able to perform independently and interpret remotely.

Competitive environment

The major players operating in the infertility drugs and devices market are Abbott Laboratories, Esco Micro Pte Ltd, Ferring BV, FUJIFILM Irvine Scientific, Hamilton Thorne, Merck KGaA, The Baker Company, The Cooper Companies, Inc., Thermo Fisher Scientific and Vitrolife. These major players operating in this market have adopted various strategies including mergers and acquisitions, R&D investments, collaborations, partnerships, regional business expansion and new product launches.

Last changes

• In November 2023, Cooper Companies completed the acquisition of several Cook Medical assets, with a particular focus on the gynecological surgery, Doppler monitoring and obstetrics markets. The purchase price was US$300 million, of which US$200 million was paid in full at closing and the remaining US$100 million was to be paid over two years in increments of US$50 million each.

• In June 2023, FUJIFILM Irvine Scientific, Inc. announced the addition of the Life Whisperer Genetics module to its Life Whisperer software suite (launched in 2021), enabling non-invasive assessment of the genetic integrity of an embryo during in vitro fertilization (IVF). Life Whisperer Genetics used in conjunction with Life Whisperer Viability uniquely helps clinically select blastocysts that are more likely to be euploid and result in pregnancy using a single platform.

To access the data contained in this document, please send an e-mail [email protected]. Don’t miss out on staying up to date – order our report now.

To find more Visiongain research reports on the pharmaceutical sector, click on the links below:

Do you have any custom requirements we can help you with? Do you need a specific country, geographic region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: [email protected]

About Visiongain

Visiongain is one of the fastest growing and most innovative independent market information providers, the company publishes hundreds market research reports which he adds to his extensive portfolio every year. These reports offer in-depth analysis of 18 industries around the world. The reports, which cover 10-year forecasts, are hundreds of pages long, contain in-depth market analysis and valuable competitive intelligence. Visiongain operates in multiple vertical markets with many synergies. These markets include automotive, aerospace, chemicals, cybersecurity, defense, energy, food and beverage, materials, packaging, pharmaceuticals and utilities. Our customized and syndicated market research reports offer you a personalized piece of market intelligence tailored to your own business needs.

contact

Visiongain Limited Reports
Telephone: +44 (0) 20 7336 6100
E-mail address: [email protected]
web: www.visiongain.com